Hui Yu

List of Publications by Year
in descending order

34 papers	2,931 citations	361413 20 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	4839 citing authors

#	Article	IF	Citations
1	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051.	7.1	658
2	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	1.1	589
3	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	1.1	329
4	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 2019, 7, 630-643.	3.4	217
5	LAG-3 Protein Expression in Nonâ€“Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	1.1	192
6	Lymphocyteâ€activation geneâ€3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	3.9	168
7	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	1.1	108
8	MHC class II expression in lung cancer. Lung Cancer, 2017, 112, 75-80.	2.0	80
9	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology, 2019, 14, 25-36.	1.1	68
10	Early detection of lung cancer by using an autoantibody panel in Chinese population. OncoImmunology, 2018, 7, e1384108.	4.6	54
11	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	1.1	49
12	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. Molecular Oncology, 2020, 14, 1947-1965.	4.6	48
13	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 2257-2265.	4.1	41
14	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treatment Reviews, 2019, 72, 15-27.	7.7	37
15	Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1083-1090.	1.1	30
16	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer, 2018, 125, 115-120.	2.0	29
17	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 895-906.	2.8	29
18	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27

#	Article	IF	Citations
19	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	10.0	25
20	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). Journal of Thoracic Oncology, 2020, 15, 1748-1757.	1.1	21
21	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. Biology, 2021, 10, 502.	2.8	21
22	Heterogeneity in Immune Marker Expression afterÂAcquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell LungÂCancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	1.1	20
23	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Frontiers in Immunology, 2021, 12, 607282.	4.8	19
24	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	1.9	13
25	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE, 2017, 12, e0172209.	2.5	13
26	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology, 2016, 11, 1711-1717.	1.1	12
27	Role of mTOR As an Essential Kinase in SCLC. Journal of Thoracic Oncology, 2020, 15, 1522-1534.	1.1	12
28	Loss of STING expression is prognostic in nonâ€“small cell lung cancer. Journal of Surgical Oncology, 2022, 125, 1042-1052.	1.7	8
29	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clinical Lung Cancer, 2018, 19, 450-456.	2.6	4
30	Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.. Journal of Clinical Oncology, 2018, 36, e24281-e24281.	1.6	4
31	NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. Clinical Lung Cancer, 2022, 23, e90-e98.	2.6	3
32	Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.. Journal of Clinical Oncology, 2018, 36, 12095-12095.	1.6	2
33	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	2.6	1
34	Evaluation of CD73 in lung cancer.. Journal of Clinical Oncology, 2017, 35, e14525-e14525.	1.6	0